NZ629843A - Identification of channelrhodopsin-2 (chop2) mutations and methods of use - Google Patents

Identification of channelrhodopsin-2 (chop2) mutations and methods of use

Info

Publication number
NZ629843A
NZ629843A NZ629843A NZ62984313A NZ629843A NZ 629843 A NZ629843 A NZ 629843A NZ 629843 A NZ629843 A NZ 629843A NZ 62984313 A NZ62984313 A NZ 62984313A NZ 629843 A NZ629843 A NZ 629843A
Authority
NZ
New Zealand
Prior art keywords
chop2
channelrhodopsin
mutations
identification
methods
Prior art date
Application number
NZ629843A
Other languages
English (en)
Inventor
Zhuo-Hua Pan
Original Assignee
Univ Wayne State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Wayne State filed Critical Univ Wayne State
Priority to NZ727041A priority Critical patent/NZ727041B2/en
Publication of NZ629843A publication Critical patent/NZ629843A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/405Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from algae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NZ629843A 2012-03-05 2013-03-05 Identification of channelrhodopsin-2 (chop2) mutations and methods of use NZ629843A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ727041A NZ727041B2 (en) 2013-03-05 Identification of channelrhodopsin-2 (chop2) mutations and methods of use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261606663P 2012-03-05 2012-03-05
PCT/US2013/029171 WO2013134295A1 (en) 2012-03-05 2013-03-05 Identification of channelrhodopsin-2 (chop2) mutations and methods of use

Publications (1)

Publication Number Publication Date
NZ629843A true NZ629843A (en) 2017-03-31

Family

ID=47892055

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ629843A NZ629843A (en) 2012-03-05 2013-03-05 Identification of channelrhodopsin-2 (chop2) mutations and methods of use

Country Status (16)

Country Link
US (3) US10947281B2 (https=)
EP (1) EP2822964B1 (https=)
JP (3) JP6395611B2 (https=)
KR (1) KR102137717B1 (https=)
CN (2) CN104334575A (https=)
AU (4) AU2013230112A1 (https=)
CA (1) CA2866405A1 (https=)
DK (1) DK2822964T3 (https=)
EA (1) EA201491643A1 (https=)
ES (1) ES2703324T3 (https=)
HU (1) HUE040487T2 (https=)
MX (1) MX360085B (https=)
NZ (1) NZ629843A (https=)
PL (1) PL2822964T3 (https=)
PT (1) PT2822964T (https=)
WO (1) WO2013134295A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2019588A4 (en) 2006-05-04 2010-11-24 Univ Wayne State RESTORATION OF VISUAL RESPONSES BY IN VIVO ADMINISTRATION OF NUCLEIC ACIDS OF RHODOPSIN
WO2011140279A1 (en) 2010-05-04 2011-11-10 Wayne State University Aav-mediated subcellular targeting of heterologous rhodopsins in retinal ganglion cells
AU2013230112A1 (en) 2012-03-05 2014-09-25 Wayne State University Identification of channelrhodopsin-2 (Chop2) mutations and methods of use
US9730888B2 (en) 2013-03-14 2017-08-15 Wayne State University Method of enhancing delivery of therapeutic compounds to the eye
JP6469669B2 (ja) 2013-07-08 2019-02-13 ビーエーエスエフ ソシエタス・ヨーロピアBasf Se オキシムエステル光開始剤
AU2015229464B2 (en) 2014-03-11 2021-07-22 Wayne State University A modified mGluR6 promoter and methods of use
RU2018142273A (ru) 2016-05-03 2020-06-03 Чжо-хуа Пань Способ улучшения опосредованной вирусами доставки генов в глаз с использованием ингибиторов протеасом
WO2017207745A1 (en) * 2016-06-03 2017-12-07 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Mutant light-inducible ion channel of channelrhodopsin
CA3034887A1 (en) * 2016-08-29 2018-03-08 Wayne State University Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof
WO2018106369A2 (en) * 2016-11-06 2018-06-14 Nanoscope Technologies Llc Optogenetic modulation by multi-characteristic opsins for vision restoration and other applications thereof
EP3609518A1 (en) * 2017-04-12 2020-02-19 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. New optogenetic tool
SI3720428T1 (sl) * 2017-12-04 2023-05-31 Laboratorios Salvat, S. A. Oftalmični lokalni sestavek, ki vsebuje dobesilno kislino za zdravljenje bolezni posteriornega očesnega segmenta
JP6567153B1 (ja) * 2018-09-28 2019-08-28 学校法人東北工業大学 対象化合物の特性の予測を行うための方法、コンピュータシステム、プログラム
WO2024226667A2 (en) * 2023-04-24 2024-10-31 Nanoscope Therapeutics Inc. Optogenetic modulation by multi-characteristic opsins for vision restoration and other applications thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4498919A (en) 1983-10-31 1985-02-12 Corning Glass Works Method for making colored photochromic prescription ophthalmic lenses
US6610287B1 (en) 1990-04-16 2003-08-26 The General Hospital Corporation Transfer and expression of gene sequences into nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
US5827702A (en) 1994-10-31 1998-10-27 Genentech, Inc. Ocular gene therapy
CA2287495A1 (en) 1997-04-21 1998-10-29 University Of Florida Materials and methods for treatment of retinal diseases
WO2000015822A1 (en) 1998-09-17 2000-03-23 University Of Florida Methods for treatment of degenerative retinal diseases
CA2406743A1 (en) 2000-04-28 2001-11-08 The Trustees Of The University Of Pennsylvania Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids
CA2442670A1 (en) 2001-04-13 2002-10-24 The Trustees Of The University Of Pennsylvania Method of treating or retarding the development of blindness
WO2003016486A2 (en) 2001-08-16 2003-02-27 Sloan Kettering Institute For Cancer Research Bio-synthetic photostimulators and methods of use
DE10216005A1 (de) 2002-04-11 2003-10-30 Max Planck Gesellschaft Verwendung von biologischen Photorezeptoren als direkt lichtgesteuerte Ionenkanäle
AU2003249318A1 (en) 2002-07-18 2004-02-09 The General Hospital Corp. Method for augmenting vision in persons suffering from photoreceptor cell degeneration
US7186699B2 (en) 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
JP2007527738A (ja) 2003-11-05 2007-10-04 ニューロヴィジョン, インコーポレイテッド 視覚を改善するための方法および装置
EP1919497B1 (en) 2005-07-22 2020-02-12 The Board of Trustees of the Leland Stanford Junior University Light-activated cation channel and uses thereof
EP2019588A4 (en) 2006-05-04 2010-11-24 Univ Wayne State RESTORATION OF VISUAL RESPONSES BY IN VIVO ADMINISTRATION OF NUCLEIC ACIDS OF RHODOPSIN
WO2011140279A1 (en) * 2010-05-04 2011-11-10 Wayne State University Aav-mediated subcellular targeting of heterologous rhodopsins in retinal ganglion cells
PL2614079T3 (pl) * 2010-09-08 2016-01-29 Max Planck Gesellschaft Zmutowana kanałowa rodopsyna 2
AU2013230112A1 (en) * 2012-03-05 2014-09-25 Wayne State University Identification of channelrhodopsin-2 (Chop2) mutations and methods of use
KR101639859B1 (ko) * 2014-03-06 2016-07-14 포항공과대학교 산학협력단 광 자극에 의한 미토콘드리아 활성의 시공간적 가역 조절 방법

Also Published As

Publication number Publication date
AU2019216638B2 (en) 2021-07-08
PL2822964T3 (pl) 2019-05-31
AU2017239601A1 (en) 2017-10-26
AU2021245195B2 (en) 2023-09-28
US20250066431A1 (en) 2025-02-27
HUE040487T2 (hu) 2019-03-28
HK1205744A1 (en) 2015-12-24
CN111378020A (zh) 2020-07-07
US10947281B2 (en) 2021-03-16
AU2013230112A1 (en) 2014-09-25
WO2013134295A1 (en) 2013-09-12
CN104334575A (zh) 2015-02-04
AU2021245195A1 (en) 2021-11-04
MX2014010664A (es) 2015-03-06
MX360085B (es) 2018-10-10
NZ727041A (en) 2022-01-28
JP6395611B2 (ja) 2018-09-26
AU2017239601B2 (en) 2019-05-16
CA2866405A1 (en) 2013-09-12
KR102137717B1 (ko) 2020-07-27
EP2822964B1 (en) 2018-08-22
KR20140132401A (ko) 2014-11-17
JP2018134098A (ja) 2018-08-30
JP2019193656A (ja) 2019-11-07
AU2019216638A1 (en) 2019-09-05
ES2703324T3 (es) 2019-03-08
JP2015510759A (ja) 2015-04-13
US20150044181A1 (en) 2015-02-12
EP2822964A1 (en) 2015-01-14
PT2822964T (pt) 2018-11-29
US20220033449A1 (en) 2022-02-03
EA201491643A1 (ru) 2015-02-27
DK2822964T3 (en) 2018-12-10

Similar Documents

Publication Publication Date Title
NZ629843A (en) Identification of channelrhodopsin-2 (chop2) mutations and methods of use
IN2014CN04498A (https=)
PH12013500715A1 (en) Anticancer fusion protein
NZ630536A (en) Therapeutic agent or prophylactic agent for dementia
SA518390954B1 (ar) لقاحات علاجية لفيروس الورم الحليمي البشري 18
EP3936141A3 (en) Anti-senescence compounds and uses thereof
PH12013500714A1 (en) Anticancer fusion protein
MX352796B (es) Proteina de fusion anticancerigena.
GB201206559D0 (en) Polypeptide
WO2013152351A3 (en) Fusion polypeptides and methods of use thereof
EP4223772A3 (en) Optimized factor viii gene
EA201401211A1 (ru) Улучшенные варианты фермента химозина
EP4374913A3 (en) Novel human serum albumin mutant
IN2014DN09963A (https=)
GB2517354A (en) Hydrochloride salt of peptide and its use in combination with other peptides for immunotherapy
PH12013501970A1 (en) Anticancer fusion protein
WO2011135222A3 (fr) Utilisation de peptides comme transporteurs destines a l'internalisation de molecules d'interet dans des cellules cibles
NZ729514A (en) Therapeutic multi-peptides t specific immune therapy for treatment of brain metastasis
EA201590601A1 (ru) Применение pedf-производных полипептидов для лечения остеоартрита
EP3925968A3 (en) Hsp70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell
EP4461371A3 (en) Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
WO2014174520A8 (en) Use of inhibitory peptides for the treatment of inflammatory diseases
DK201370709A (en) Protein for use as a medicament
WO2015143339A3 (en) Enhanced influenza hemagglutinin binders
GB201019467D0 (en) Therapeutic agent

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 05 MAR 2020 BY SHELSTON IP PTY LTD

Effective date: 20170808

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 MAR 2021 BY COMPUTER PACKAGES INC

Effective date: 20200218

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 MAR 2022 BY COMPUTER PACKAGES INC

Effective date: 20210306

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 MAR 2023 BY COMPUTER PACKAGES INC

Effective date: 20220217

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 MAR 2024 BY CPA GLOBAL

Effective date: 20230120

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 MAR 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240118

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 MAR 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20250116